White Paper on Testing for Asbestos in Cosmetic Products Containing Talc
Talc is used in a variety of consumer products, including cosmetics. Some talc deposits may contain Asbestos, a known human carcinogen. The FDA has published a white paper describing the IWGACP scientific opinions on testing methods for asbestos in cosmetic products containing talc.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


Talc (CAS number: 14807-96-6) is a naturally occurring mineral, consisting of hydrous magnesium silicate and it can contain sometimes small quantities of aluminium silicate. It used in a wide variety of consumer products, including cosmetics. In cosmetics and personal care products, Talc is usually used as an abrasive, absorbent, anticaking, bulking, opacifying and skin protecting agent. The U.S. Food and Drug Administration (FDA) includes Talc (magnesium silicate) on its list of substances Generally Recognized As Safe (GRAS) for use in food as an anticaking agent and it also allows the use of talc as an indirect food additive (colorant in polymers) and as colorant in drugs. (see previous post)

Some Talc deposits may contain asbestos and other magnesium silicate minerals, notably members of the amphibole group. Asbestos is a term used to describe some silicate minerals that have an unusual fibrous (asbestiform) habit of crystal growth. Asbestos properties (flexibility, durability and heat resistance) make it useful for commercial purposes. Nevertheless, Asbestos is a human carcinogen and has well-documented health risks (e.g., inflammation, pleural disease, lung cancers, malignant mesothelioma).

Responding to test results indicating the presence of asbestos, the U.S. cosmetics industry implemented voluntarily a protocol to test cosmetic talc for asbestos using the Cosmetic, Toiletry, and Fragrance Association (CTFA) J4-1 method. A similar method is used by talc suppliers to the pharmaceutical industry. Both protocols have long-recognized shortcomings in specificity and sensitivity to detect the presence of asbestos and similar mineral particles that may pose a health concern.


Although the FDA regularly samples products containing talc for the presence of asbestos, laboratories that analyze the same product may reach to different conclusions. That happens because there are no uniform standard for identifying and counting asbestos fibers.

The FDA has published a white paper regarding scientific opinions on testing methods for asbestos in cosmetic products containing talc. The scientific opinions are from an Interagency Working Group on Asbestos in Consumer Products (IWGACP) and do not represent recommendations or policies of FDA or any other federal agency. IWGACP is composed of subject matter experts from eight different U.S. federal agencies.

The IWGACP’s aim was to develop a consensus document to support the development of standardized testing methods to improve the sensitivity and consistency of analyses, and inter-laboratory concurrence when reporting asbestos (or other amphibole mineral particles) in talc.

The Interagency Working Group recommends the use of both polarized light microscopy and transmission electron microscopy methods to identify/report the presence of these compounds. Moreover, it advises to report all asbestos and all amphibole and chrysotile particles that have a length greater than or equal to 0.5 µm and a ratio of length to width above or equal to 3:1. Other scientific opinions are described in the white paper.

The IWGACP proposes further research in some areas, like sampling methods for talc and talc-containing cosmetics, in order to promote reliability, sensitivity and interlaboratory agreement of analytical methods.

The FDA will conduct another talc sampling assignment in 2022. The Agency will test 50 additional talc-containing cosmetic products samples and communicate any results that indicate the presence of asbestos, if found.

If you wish to get more information regarding this or other subjects, feel free to contact us at info@criticalcatalyst.com.


  1. Interagency Working Group On Asbestos In Consumer Products (IWGACP). White Paper: IWGACP Scientific Opinions on Testing Methods For Asbestos In Cosmetic Products Containing Talc. December 2021.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »